Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Pathologic complete response rates improved with the neoadjuvant and adjuvant...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic...

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients ( Dr Luca Gianni - San Raffaele Hospital, Milan, Italy )

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for...

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer ( Dr Luca Gianni - San Raffaele Hospital, Milan, Italy )

The emerging role of immunotherapy for the treatment of early and advanced...

Dr Rita Nanda - UChicago Medicine, Chicago, USA

The emerging role of immunotherapy for the treatment of early and advanced breast cancer ( Dr Rita Nanda - UChicago Medicine, Chicago, USA )

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Could trastuzumab deruxtecan become the new standard of care for pretreated...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

LYRA: Maintenance therapy with daratumumab improves depth of response and...

Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA

LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with...

Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center...

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )

More from ecancer